



Novartis India Limited  
Registered Office:  
Inspire BKC  
Part of 601 & 701  
Bandra Kurla Complex  
Bandra (East)  
Mumbai – 400 051  
Maharashtra, India  
Tel +91 22 50243000  
Fax +91 22 50243010  
Email: india.investors@novartis.com  
CIN No. L24200MH1947PLC006104  
Website: www.novartis.in

June 11, 2020

To,  
The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001  
**Scrip code:** 500672

**Sub.: Intimation of meeting of the Board of Directors of Novartis India Limited (“the Company”)**

**Ref.: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

Please be informed that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, June 19, 2020, through video-conferencing in accordance with the notification issued by the Ministry of Corporate Affairs dated March 19, 2020, *inter alia* to consider the Audited Financial Results of the Company for the fourth quarter and Financial Year ended March 31, 2020 and recommendation of final dividend on Equity Share, if any, for the said year.

Further, please note that pursuant to the Company's Code of Conduct for regulating, monitoring and reporting share trading by designated persons, as informed earlier vide our letter dated March 31, 2020, the trading window for dealing in securities of the Company is closed from Wednesday, April 1, 2020 and shall continue to be closed till June 21, 2020 (both days inclusive). The trading window shall re-open with effect from June 22, 2020.

Further, a copy of this notice will be published in the selected newspapers and will be made available on the website of the Company [www.novartis.in](http://www.novartis.in).

This is for your information.

Thanking You.

Yours sincerely,

**For Novartis India Limited**

**Trivikram Guda  
Company Secretary &  
Compliance Officer**